Иностранные статьи

Logo1

Rytkin E., Mirzaev K.B., Smirnov V.V., et al. Assessment of CYP2C19, ABCB1, CYP3A5 Genes Polymorphisms’ and CYP3A4 Isoenzyme Activity Influence on Major Adverse Cardiovascular Events Among Pat ients with an Acute Coronary Sy ndrome Undergoing Percutaneou
Sychev D, Minnigulov R, Bochkov P, et al. Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery. High Blood Press Cardiovasc Prev. 2019 Oct 15.
Zastrozhin MS, Brodyansky VM, Skryabin VY, et al. Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. Pharmgenomics Pers Med. 2017;10:209-215.
Denisenko NP, Sychev DA, Sizova ZM et al. Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. Pharmacogenomics and Personalized Medicine 2017, 10:253-259
Denisenko NP, Sychev DA, Sizova ZM, et al. CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. 2018:11;107—112.
Dorofeeva MN, Shikh EV, Sizova ZM, et al. Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects Pharmgenomics Pers Med. 2019;12:329-339.
Fedorinov DS, Mirzaev KB, Ivashchenko DV, et al. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). Drug Metab Pers Ther. 2018 May 8.
Fedorinov DS, Mirzaev KB, Mustafina VR, et al. Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA). Drug Metab P
Ivashchenko D, Rusin I, Sychev D, et al. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk. Medicina (Kaunas). 2013;49(12):517-21.
Ivashchenko DV, Rudik AV, Poloznikov AA, et al. Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. Drug Metab Pers Ther. 2018 May 4.
Kryukov AV, Sychev DA, Andreev DA, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmacogenomics and Personalized Medicine. 2018,11:43—49
Mirzaev K, Sychev D, Arutyunyan G, et al. Cytochrome 2C19 Enzyme Polymorphism Frequency in Different Indigenous Ethnic Groups in Russian Federation: A Systematic Review J Pharmacogenomics Pharmacoproteomics 2014 5:136.
Mirzaev KB, Fedorinov DS, Ivashchenko DV, Sychev DA. ADME pharmacogenetics: future outlook for Russia. Pharmacogenomics. 2019 Aug 1.
Mirzaev KB, Kiselev Y, Ivashchenko DV, et al. Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team. Br J Clin Pharmacol
Mirzaev KB, Osipova DV, Kitaeva EJ, et al. Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. Drug Metab Pers Ther. 2019 Sep 27.
Mirzaev KB, Samsonova KI, Potapov PP, et al. Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel. Mol Biol Rep. 2019 May 17.
Mirzaev KB, Sychev DA, Ryzhikova KA et al. Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. Genetic testing and molecular biomarkers. 2017,12:1-7
Mirzaev KB, Zelenskaya EM, Barbarash OL et al. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndromePharmgenomics Pers Med. 2017;10:107-114.
Mirzaev KB., Rytkin E., Ryzhikova KA., et al. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metabolism and Personalized Therapy 2018.
Rytkin E, Mirzaev KB, Grishina EA et al. Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients? Pharmacogenomics and Personalized Medicine 2017, 10:243-245.

Страница 1 из 2

Rytkin E., Mirzaev K.B., Smirnov V.V., et al. Assessment of CYP2C19, ABCB1, CYP3A5 Genes Polymorphisms’ and CYP3A4 Isoenzyme Activity Influence on Major Adverse Cardiovascular Events Among Pat ients with an Acute Coronary Sy ndrome Undergoing Percutaneou

Sychev D, Minnigulov R, Bochkov P, et al. Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery. High Blood Press Cardiovasc Prev. 2019 Oct 15.

Zastrozhin MS, Brodyansky VM, Skryabin VY, et al. Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. Pharmgenomics Pers Med. 2017;10:209-215.

Denisenko NP, Sychev DA, Sizova ZM et al. Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. Pharmacogenomics and Personalized Medicine 2017, 10:253-259

Denisenko NP, Sychev DA, Sizova ZM, et al. CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. 2018:11;107—112.

Dorofeeva MN, Shikh EV, Sizova ZM, et al. Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects Pharmgenomics Pers Med. 2019;12:329-339.

Fedorinov DS, Mirzaev KB, Ivashchenko DV, et al. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). Drug Metab Pers Ther. 2018 May 8.

Fedorinov DS, Mirzaev KB, Mustafina VR, et al. Pharmacogenetic testing by polymorphic markers G1846A (CYP2D64) and C100T (CYP2D610) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA). Drug Metab P

Ivashchenko D, Rusin I, Sychev D, et al. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk. Medicina (Kaunas). 2013;49(12):517-21.

Ivashchenko DV, Rudik AV, Poloznikov AA, et al. Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. Drug Metab Pers Ther. 2018 May 4.

Kryukov AV, Sychev DA, Andreev DA, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmacogenomics and Personalized Medicine. 2018,11:43—49

Mirzaev K, Sychev D, Arutyunyan G, et al. Cytochrome 2C19 Enzyme Polymorphism Frequency in Different Indigenous Ethnic Groups in Russian Federation: A Systematic Review J Pharmacogenomics Pharmacoproteomics 2014 5:136.

Mirzaev KB, Fedorinov DS, Ivashchenko DV, Sychev DA. ADME pharmacogenetics: future outlook for Russia. Pharmacogenomics. 2019 Aug 1.

Mirzaev KB, Kiselev Y, Ivashchenko DV, et al. Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team. Br J Clin Pharmacol

Mirzaev KB, Osipova DV, Kitaeva EJ, et al. Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. Drug Metab Pers Ther. 2019 Sep 27.

Mirzaev KB, Samsonova KI, Potapov PP, et al. Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel. Mol Biol Rep. 2019 May 17.

Mirzaev KB, Sychev DA, Ryzhikova KA et al. Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. Genetic testing and molecular biomarkers. 2017,12:1-7

Mirzaev KB, Zelenskaya EM, Barbarash OL et al. CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndromePharmgenomics Pers Med. 2017;10:107-114.

Mirzaev KB., Rytkin E., Ryzhikova KA., et al. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metabolism and Personalized Therapy 2018.

Rytkin E, Mirzaev KB, Grishina EA et al. Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients? Pharmacogenomics and Personalized Medicine 2017, 10:243-245.

Популярные теги

Последние изменения

Наши Партнеры

Вход